Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Several makers of hepatitis C drugs are limiting health care providers’ access to the 340B Drug Pricing Program’s discounts.
The Supreme Court refused to hear Merck’s arguments on a hepatitis C patent, so the previous ruling in Gilead’s favor stands.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.
Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.
Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
In a Phase II study, the drug was safe and well tolerated, and a small number of people achieved benchmarks of success against the virus.
A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.
Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.